Pharming Announces Instructions for Exchanging Listed Ordinary Shares into Nasdaq Listed ADSs
Costs for conversion of Ordinary Shares into ADS s waived by JP Morgan Chase for initial four weeks after today
LEIDEN, Netherlands, Dec. 22, 2020 /PRNewswire/ Pharming Group N.V. ( Pharming or the Company ) (Euronext Amsterdam: PHARM), a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs, today separately announced that in connection with the listing of American Depositary Shares ( ADSs ) representing ordinary shares of nominal value of €0.01 each in the capital of the Company ( Ordinary Shares ) on the Nasdaq Global Market ( Nasdaq ), the United States Securities and Exchange Commission has declared effective registration statements on Form F-1 and F-6 with respect to such securities, Nasdaq has approved the ADSs for listing, and ADSs will begin tra
Pharming Announces Instructions for Exchanging Listed Ordinary Shares into Nasdaq Listed ADSs | ANP Pers Support perssupport.nl - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from perssupport.nl Daily Mail and Mail on Sunday newspapers.
Pharming Reports on Extraordinary General Meeting of Shareholders
LEIDEN, Netherlands, Dec. 11, 2020 /PRNewswire/ Pharming Group N.V. ( Pharming or the Company ) (Euronext Amsterdam: PHARM) announces that at its Extraordinary General Meeting of shareholders (EGM), held today, all proposals were approved. As a result, the one-tier board structure has become effective, and Barbara Yanni and Mark Pykett have been appointed as non-executive board members.
A recording of the webcast and the presentation slides from today s EGM are available on the Company s website: https://www.pharming.com/investors/shareholder-meetings
About Pharming Group N.V.
Pharming Group N.V. is a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs.
Pharming Reports on Extraordinary General Meeting of Shareholders | ANP Pers Support perssupport.nl - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from perssupport.nl Daily Mail and Mail on Sunday newspapers.
(2)
Highlights:
First patient treated in second clinical trial globally investigating the use of RUCONEST to prevent severe SARS-CoV-2 infections in hospitalised patients with confirmed COVID-19
Planned expansion to multiple centres across the US
LEIDEN, The Netherlands, Dec. 10, 2020 /PRNewswire/ Pharming Group N.V. ( Pharming or the Company ) (Euronext Amsterdam: PHARM) today announced that the first patient has been enrolled in a randomised, open label, parallel group, controlled, pilot clinical trial in up to 120 patients hospitalised with confirmed COVID-19 treated with RUCONEST (recombinant human C1 inhibitor) for the prevention of severe SARS-CoV-2 infections at the Valley Hospital in Ridgewood, New Jersey in the United States.